The Department of Neurology at Amrita Hospital, Faridabad, successfully organized an academic seminar titled "A New Era in Alzheimer's Disease", bringing together neurologists, physicians, and healthcare professionals to discuss the latest advances in the diagnosis and treatment of Alzheimer's disease.
The event was conducted in collaboration with Eli Lilly India and focused on emerging disease-modifying therapies that are reshaping the management of early Alzheimer's disease. The scientific program was inaugurated with an introduction by the Eli Lilly team, followed by an engaging session on the paradigm shift in Alzheimer's disease diagnosis, delivered by Dr. Dinesh Chaudhari, Therapy Lead – Neurosciences, Eli Lilly. His presentation highlighted the importance of early recognition, advances in biomarkers, and evolving diagnostic approaches that enable timely intervention.
The keynote address was delivered by Dr. Sanjay Pandey, Professor and Head, Department of Neurology and Stroke Medicine, Amrita Institute of Medical Sciences, Faridabad. Dr. Pandey provided an in-depth overview of Donanemab (LormaIzi) and its role in the treatment of early symptomatic Alzheimer's disease, discussing evidence from recent clinical trials, patient selection, safety considerations, and its potential to slow disease progression.
The seminar concluded with an interactive panel discussion and audience Q&A session, allowing participants to exchange ideas, clarify clinical concerns, and discuss the practical implementation of these advances in routine neurological practice.
This educational initiative reflects Amrita Hospital's commitment to academic excellence, continuous medical education, and the adoption of cutting-edge therapies for neurological disorders. By fostering meaningful scientific dialogue and promoting evidence-based practice, the Department of Neurology continues to strengthen its position as a leading center for neurological care, research, and innovation. Such programs ensure that healthcare professionals remain equipped with the latest knowledge to deliver the highest standards of patient care, ultimately improving outcomes for individuals living with Alzheimer's disease and other neurodegenerative disorders.
